Please assess the completion status of the following clinical trial:

Trial Title: Intensified Post Remission Therapy Containing PEG-Asparaginase

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with previously untreated ALL subtypes L1 and L2.~* Patients with de novo Philadelphia (Ph)+ ALL (i.e. excluding those that are after blastic of CML) are eligible. However they will be referred to allogeneic hematopoietic stem cell transplantation and will continue on the study until they are ready to undergo the transplantation. At that time they will discontinue the study. Patients who are unable to undergo allogeneic transplantation will continue on the study.~* Presence of 25% or more of lymphoblasts in the bone marrow by FAB criteria, confirmed by TdT positivity or by flow cytometry with standard ALL markers.~* Patients may have received prior steroids.~* Age: 18 - 55 years~* Signed Informed Consent~Exclusion Criteria:~* Patients with Burkitt's ALL (L3 subtype) or CML lymphoblastic crisis are not eligible (including CML patients who present with ALL blastic crisis).~* Psychological or emotional disorders which will make a valid informed consent impossible.~* Bilirubin \>1.5 mg/dl, creatinine \> 2.5 mg/dl~* Symptomatic congestive heart failure or unstable angina~* Pregnant or lactating females~* Known HIV positive status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Intensified Post-Remission: MTX/LV/PEG-Asparaginase (Type: EXPERIMENTAL): Daunorubicin 60 mg/m2 iv on days 1, 2, 3 Vincristine 1.4 mg/m2 iv on days 1, 8, 15, 22 Peg-Asparaginase 2000 U/m2 iv on day 15 Prednisone 60 mg/m2 mg po on days 1-28 MTX 12 mg IT on days 8 \& 15

Based on this trial design, predict the completion outcome and termination type (if applicable).